Literature DB >> 30352839

Circulating Receptor Activator of Nuclear Factor-κB (RANK), RANK ligand (RANKL), and Mammographic Density in Premenopausal Women.

Adetunji T Toriola1, Catherine M Appleton2, Xiaoyu Zong3, Jingqin Luo3, Katherine Weilbaecher4, Rulla M Tamimi5, Graham A Colditz3.   

Abstract

The receptor activator of nuclear factor-κB (RANK) pathway plays essential roles in breast development. Mammographic density is a strong risk factor for breast cancer, especially in premenopausal women. We, therefore, investigated the associations of circulating RANK and soluble RANK ligand (sRANKL) with mammographic density in premenopausal women. Mammographic density was measured as volumetric percent density in 365 cancer-free premenopausal women (mean age, 47.5 years) attending screening mammogram at the Washington University School of Medicine (St. Louis, MO). We used linear regression models adjusted for confounders, to compare the least-square means of volumetric percent density across tertiles of circulating RANK and sRANKL. Furthermore, because RANKL levels in mammary tissue are modulated by progesterone, we stratified analyses by progesterone levels. The mean volumetric percent density increased across tertiles of circulating RANK from 8.6% in tertile 1, to 8.8% in tertile 2, and 9.5% in tertile 3 (P trend = 0.02). For sRANKL, the mean volumetric percent density was 8.5% in tertile 1, 9.4% in tertile 2, and 9.0% in tertile 3 (P trend = 0.30). However, when restricted to women with higher progesterone levels, the mean volumetric percent density increased from 9.1% in sRANKL tertile 1 to 9.5% in tertile 2, and 10.1% in tertile 3 (P trend = 0.01). Circulating RANK was positively associated with volumetric percent density, while circulating sRANKL was positively associated with volumetric percent density among women with higher progesterone levels. These findings support the inhibition of RANKL signaling as a pathway to reduce mammographic density and possibly breast cancer incidence in high-risk women with dense breasts. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30352839      PMCID: PMC6784533          DOI: 10.1158/1940-6207.CAPR-18-0199

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  47 in total

Review 1.  RANKL inhibition: a promising novel strategy for breast cancer treatment.

Authors:  Eva González-Suárez
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.405

2.  Progesterone induces adult mammary stem cell expansion.

Authors:  Purna A Joshi; Hartland W Jackson; Alexander G Beristain; Marco A Di Grappa; Patricia A Mote; Christine L Clarke; John Stingl; Paul D Waterhouse; Rama Khokha
Journal:  Nature       Date:  2010-06-10       Impact factor: 49.962

3.  RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.

Authors:  Emma Nolan; François Vaillant; Daniel Branstetter; Bhupinder Pal; Göknur Giner; Lachlan Whitehead; Sheau W Lok; Gregory B Mann; Kathy Rohrbach; Li-Ya Huang; Rosalia Soriano; Gordon K Smyth; William C Dougall; Jane E Visvader; Geoffrey J Lindeman
Journal:  Nat Med       Date:  2016-06-20       Impact factor: 53.440

4.  The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development.

Authors:  J E Fata; Y Y Kong; J Li; T Sasaki; J Irie-Sasaki; R A Moorehead; R Elliott; S Scully; E B Voura; D L Lacey; W J Boyle; R Khokha; J M Penninger
Journal:  Cell       Date:  2000-09-29       Impact factor: 41.582

5.  Soluble RANKL and risk of nontraumatic fracture.

Authors:  Georg Schett; Stefan Kiechl; Kurt Redlich; Friedrich Oberhollenzer; Siegfried Weger; Georg Egger; Agnes Mayr; Josef Jocher; Qingbo Xu; Peter Pietschmann; Steven Teitelbaum; Josef Smolen; Johann Willeit
Journal:  JAMA       Date:  2004-03-03       Impact factor: 56.272

6.  Prevalence of mammographically dense breasts in the United States.

Authors:  Brian L Sprague; Ronald E Gangnon; Veronica Burt; Amy Trentham-Dietz; John M Hampton; Robert D Wellman; Karla Kerlikowske; Diana L Miglioretti
Journal:  J Natl Cancer Inst       Date:  2014-09-12       Impact factor: 13.506

7.  Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort.

Authors:  Renée T Fortner; Danja Sarink; Helena Schock; Theron Johnson; Anne Tjønneland; Anja Olsen; Kim Overvad; Aurélie Affret; Mathilde His; Marie-Christine Boutron-Ruault; Heiner Boeing; Antonia Trichopoulou; Androniki Naska; Philippos Orfanos; Domenico Palli; Sabina Sieri; Amalia Mattiello; Rosario Tumino; Fulvio Ricceri; H Bas Bueno-de-Mesquita; Petra H M Peeters; Carla H Van Gils; Elisabete Weiderpass; Eiliv Lund; J Ramón Quirós; Antonio Agudo; Maria-José Sánchez; María-Dolores Chirlaque; Eva Ardanaz; Miren Dorronsoro; Tim Key; Kay-Tee Khaw; Sabina Rinaldi; Laure Dossus; Marc Gunter; Melissa A Merritt; Elio Riboli; Rudolf Kaaks
Journal:  BMC Med       Date:  2017-02-08       Impact factor: 8.775

8.  Increased breast tissue receptor activator of nuclear factor-κB ligand (RANKL) gene expression is associated with higher mammographic density in premenopausal women.

Authors:  Adetunji T Toriola; Ha X Dang; Ian S Hagemann; Catherine M Appleton; Graham A Colditz; Jingqin Luo; Christopher A Maher
Journal:  Oncotarget       Date:  2017-05-17

9.  Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer.

Authors:  Stefan Kiechl; Daniel Schramek; Martin Widschwendter; Evangelia-Ourania Fourkala; Alexey Zaikin; Allison Jones; Bernadette Jaeger; Brigitte Rack; Wolfgang Janni; Christoph Scholz; Johann Willeit; Siegfried Weger; Agnes Mayr; Andrew Teschendorff; Adam Rosenthal; Lindsay Fraser; Susan Philpott; Louis Dubeau; Mohammed Keshtgar; Rebecca Roylance; Ian J Jacobs; Usha Menon; Georg Schett; Josef M Penninger
Journal:  Oncotarget       Date:  2017-01-17

Review 10.  The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis.

Authors:  Elizabeth Anderson
Journal:  Breast Cancer Res       Date:  2002-07-24       Impact factor: 6.466

View more
  4 in total

1.  Premenopausal Plasma Osteoprotegerin and Breast Cancer Risk: A Case-Control Analysis Nested within the Nurses' Health Study II.

Authors:  Rulla M Tamimi; A Heather Eliassen; Joanne Kotsopoulos; Emma E McGee; Susana Lozano-Esparza; Judy E Garber; Jennifer Ligibel; Laura C Collins; Kornelia Polyak; Myles Brown; Steven Narod
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-04-10       Impact factor: 4.254

2.  Randomized Phase IIB Trial of the Lignan Secoisolariciresinol Diglucoside in Premenopausal Women at Increased Risk for Development of Breast Cancer.

Authors:  Carol J Fabian; Seema A Khan; Judy E Garber; William C Dooley; Lisa D Yee; Jennifer R Klemp; Jennifer L Nydegger; Kandy R Powers; Amy L Kreutzjans; Carola M Zalles; Trina Metheny; Teresa A Phillips; Jinxiang Hu; Devin C Koestler; Prabhakar Chalise; Nanda Kumar Yellapu; Cheryl Jernigan; Brian K Petroff; Stephen D Hursting; Bruce F Kimler
Journal:  Cancer Prev Res (Phila)       Date:  2020-04-20

3.  Investigation of The Relationship of TNFRSF11A Gene Polymorphisms with Breast Cancer Development and Metastasis Risk in Patients with BRCA1 Or BRCA2 Pathogenic Variants Living in The Trakya Region of Turkey.

Authors:  K Özdemir; H Gürkan; S Demir; E Atli; Y Özen; A Sezer; N Tunçbilek; I Çicin
Journal:  Balkan J Med Genet       Date:  2021-03-23       Impact factor: 0.519

4.  Changes in adiposity over the life course and gene expression in postmenopausal women.

Authors:  Yunan Han; Graham A Colditz; Adetunji T Toriola
Journal:  Cancer Med       Date:  2022-03-19       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.